Terms: = Endocrine gland cancer AND TNFRSF17, BCMA, 608, ENSG00000048462, CD269, Q02223, BCM AND Treatment
35 results:
1. Pathologic tumor response to neoadjuvant therapy in resected pancreatic cancer: does it affect prognosis?
Donisi G; Nappo G; Pacilli M; Capretti GL; Spaggiari P; Sollai M; Bozzarelli S; Zerbi A
Updates Surg; 2023 Sep; 75(6):1497-1508. PubMed ID: 37578734
[TBL] [Abstract] [Full Text] [Related]
2. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.
Newhouse R; Nelissen E; El-Shakankery KH; Rogozińska E; Bain E; Veiga S; Morrison J
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD006910. PubMed ID: 37407274
[TBL] [Abstract] [Full Text] [Related]
3. Efficacy and safety of apatinib combined with liposomal doxorubicin or paclitaxel versus liposomal doxorubicin or paclitaxel monotherapy in patients with recurrent platinum-resistant ovarian cancer.
Yang H; Geng A; Wang Z; Wu C
J Obstet Gynaecol Res; 2023 Jun; 49(6):1611-1619. PubMed ID: 36988159
[TBL] [Abstract] [Full Text] [Related]
4. The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study.
Yang L; Su J; Wang W; Zhou F
World J Surg Oncol; 2023 Jan; 21(1):19. PubMed ID: 36691032
[TBL] [Abstract] [Full Text] [Related]
5. Response to targeted radionuclide therapy with [
Prado-Wohlwend S; Del Olmo-García MI; Bello-Arques P; Merino-Torres JF
Front Endocrinol (Lausanne); 2022; 13():957172. PubMed ID: 36339441
[TBL] [Abstract] [Full Text] [Related]
6. The relationship between papillary thyroid cancer and triglyceride/glucose index, which is an indicator of insulin resistance.
Alkurt EG; Şahin F; Tutan B; Canal K; Turhan VB
Eur Rev Med Pharmacol Sci; 2022 Sep; 26(17):6114-6120. PubMed ID: 36111913
[TBL] [Abstract] [Full Text] [Related]
7. Identification of copy number variation-driven molecular subtypes informative for prognosis and treatment in pancreatic adenocarcinoma of a Chinese cohort.
Zhan Q; Wen C; Zhao Y; Fang L; Jin Y; Zhang Z; Zou S; Li F; Yang Y; Wu L; Jin J; Lu X; Xie J; Cheng D; Xu Z; Zhang J; Wang J; Deng X; Chen H; Peng C; Li H; Zhang H; Fang H; Wang C; Shen B
EBioMedicine; 2021 Dec; 74():103716. PubMed ID: 34839264
[TBL] [Abstract] [Full Text] [Related]
8. Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer.
Yan S; Fang J; Chen Y; Xie Y; Zhang S; Zhu X; Fang F
BMC Cancer; 2020 Dec; 20(1):1205. PubMed ID: 33287740
[TBL] [Abstract] [Full Text] [Related]
9. Patients triaged to neoadjuvant chemotherapy have higher rates of sarcopenia: An opportunity for prehabilitation.
Fadadu PP; Polen-De CL; McGree ME; Weaver AL; Moynagh MR; Takahashi N; Langstraat CL; Cliby WA; Kumar A
Gynecol Oncol; 2021 Jan; 160(1):40-44. PubMed ID: 33109391
[TBL] [Abstract] [Full Text] [Related]
10. The Transareola Endoscopic Approach Yields Adequate Oncological Dissection as Open Approach in the treatment of Papillary Thyroid Carcinoma.
Gao H; Chen C; Liu X; Xu N; Wang Y; Qu R; Yu X
Surg Laparosc Endosc Percutan Tech; 2019 Dec; 29(6):489-492. PubMed ID: 31584497
[TBL] [Abstract] [Full Text] [Related]
11. Bioactivation of Napabucasin Triggers Reactive Oxygen Species-Mediated cancer Cell Death.
Froeling FEM; Swamynathan MM; Deschênes A; Chio IIC; Brosnan E; Yao MA; Alagesan P; Lucito M; Li J; Chang AY; Trotman LC; Belleau P; Park Y; Rogoff HA; Watson JD; Tuveson DA
Clin Cancer Res; 2019 Dec; 25(23):7162-7174. PubMed ID: 31527169
[TBL] [Abstract] [Full Text] [Related]
12. Involvement of NORAD/miR-608/STAT3 axis in carcinostasis effects of physcion 8-O-β-glucopyranoside on ovarian cancer cells.
Yang X; Yan Y; Chen Y; Li J; Yang J
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):2855-2865. PubMed ID: 31299866
[TBL] [Abstract] [Full Text] [Related]
13. CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabine.
Sonbol MB; Ahn DH; Goldstein D; Okusaka T; Tabernero J; Macarulla T; Reni M; Li CP; O'Neil B; Van Cutsem E; Bekaii-Saab T
Future Oncol; 2019 Apr; 15(12):1295-1302. PubMed ID: 30768369
[TBL] [Abstract] [Full Text] [Related]
14. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
Vergote I; Coens C; Nankivell M; Kristensen GB; Parmar MKB; Ehlen T; Jayson GC; Johnson N; Swart AM; Verheijen R; McCluggage WG; Perren T; Panici PB; Kenter G; Casado A; Mendiola C; Stuart G; Reed NS; Kehoe S; ;
Lancet Oncol; 2018 Dec; 19(12):1680-1687. PubMed ID: 30413383
[TBL] [Abstract] [Full Text] [Related]
15. A Comparative Analysis of Survival and Funding Discrepancies in cancers With High Mortality.
Hall BR; Cannon A; Atri P; Wichman CS; Smith LM; Kumar S; Batra SK; Wang H; Ganti AK; Sasson AR; Are C
Ann Surg; 2020 Feb; 271(2):296-302. PubMed ID: 30188400
[TBL] [Abstract] [Full Text] [Related]
16. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
Neoptolemos JP; Palmer DH; Ghaneh P; Psarelli EE; Valle JW; Halloran CM; Faluyi O; O'Reilly DA; Cunningham D; Wadsley J; Darby S; Meyer T; Gillmore R; Anthoney A; Lind P; Glimelius B; Falk S; Izbicki JR; Middleton GW; Cummins S; Ross PJ; Wasan H; McDonald A; Crosby T; Ma YT; Patel K; Sherriff D; Soomal R; Borg D; Sothi S; Hammel P; Hackert T; Jackson R; Büchler MW;
Lancet; 2017 Mar; 389(10073):1011-1024. PubMed ID: 28129987
[TBL] [Abstract] [Full Text] [Related]
17. Preoperative defining system for pancreatic head cancer considering surgical resection.
Yang SJ; Hwang HK; Kang CM; Lee WJ
World J Gastroenterol; 2016 Jul; 22(26):6076-82. PubMed ID: 27468199
[TBL] [Abstract] [Full Text] [Related]
18. Oncologic Safety of Robot Thyroid Surgery for Papillary Thyroid Carcinoma: A Comparative Study of Robot versus Open Thyroid Surgery Using Inverse Probability of treatment Weighting.
Sung TY; Yoon JH; Han M; Lee YH; Lee YM; Song DE; Chung KW; Kim WB; Shong YK; Hong SJ
PLoS One; 2016; 11(6):e0157345. PubMed ID: 27285846
[TBL] [Abstract] [Full Text] [Related]
19. Targeting miR-21-3p inhibits proliferation and invasion of ovarian cancer cells.
Báez-Vega PM; Echevarría Vargas IM; Valiyeva F; Encarnación-Rosado J; Roman A; Flores J; Marcos-Martínez MJ; Vivas-Mejía PE
Oncotarget; 2016 Jun; 7(24):36321-36337. PubMed ID: 27166999
[TBL] [Abstract] [Full Text] [Related]
20. Adjuvant Trametinib Delays the Outgrowth of Occult Pancreatic cancer in a Mouse Model of Patient-Derived Liver Metastasis.
Newhook TE; Lindberg JM; Adair SJ; Kim AJ; Stelow EB; Rahma OE; Parsons JT; Bauer TW
Ann Surg Oncol; 2016 Jun; 23(6):1993-2000. PubMed ID: 26847682
[TBL] [Abstract] [Full Text] [Related]
[Next]
